SCHEMBL12488267

SCHEMBL12488267

COC(=O)c1cc(I)c(C2CCC2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.38
PDK2 Q15119 1/20 0.38
PDK4 Q16654 1/20 0.38
SLC6A3 Q01959 2/20 0.37
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
FASN P49327 6/20 0.35
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
FGFR3 P22607 1/20 0.35
KDR P35968 1/20 0.35
OPRK1 P41145 1/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
FUCA1 P04066 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12488096 0.94 PDK2 (0.41) CFTRPDK2PDK4SLC6A3KDM4E
SCHEMBL12488192 0.88 PDK2 (0.38) CFTRPDK2PDK4SLC6A3KDM4E
SCHEMBL18432288 0.86 PDK2 (0.40) CFTRPDK2PDK4SLC6A3KDM4E
SCHEMBL12488784 0.83 MAPT (0.38) FASNMAPT
SCHEMBL12489172 0.83 CFTR (0.36) CFTRPDK2PDK4SLC6A3KDM4E
SCHEMBL12489091 0.82 FASN (0.39) PDK2PDK4SLC6A3KDM4EALDH1A1
SCHEMBL12686869 0.82 KDM4E (0.43) CFTRPDK2PDK4SLC6A3KDM4E
SCHEMBL12488074 0.82 CFTR (0.38) CFTRPDK2PDK4SLC6A3KDM4E
SCHEMBL18432633 0.81 SLC6A3 (0.43) PDK2PDK4SLC6A3KDM4EALDH1A1
SCHEMBL12488865 0.81 FASN (0.51) CFTRPDK2PDK4SLC6A3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055152-A Combination therapy of FASN inhibitors with thyroid hormone receptor agonists 萨吉米特生物科学公司 2026-05-15 CN disclosed
EP-4731212-A1 COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS Sagimet Biosciences Inc. (US) 2026-04-29 EP disclosed
US-20260048061-A1 COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS SAGIMET BIOSCIENCES INC (US) 2026-02-19 US disclosed
US-12551490-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2026-02-17 US disclosed
US-20250017938-A1 COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS SAGIMET BIOSCIENCES INC. 2025-01-16 US disclosed
WO-2024263785-A1 COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS SAGIMET BIOSCIENCES INC. (US) 2024-12-26 WO disclosed
US-20240400552-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2024-12-05 US disclosed
US-20230405016-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS SAGIMET BIOSCIENCES INC. 2023-12-21 US disclosed
CN-116139138-A Heterocyclic modulators of lipid synthesis 3-V生物科学股份有限公司 2023-05-23 CN disclosed
US-11622968-B2 Heterocyclic modulators of lipid synthesis SAGIMET BIOSCIENCES INC. (US) 2023-04-11 US disclosed
US-8871790-B2 Heterocyclic modulators of lipid synthesis 3-V BIOSCIENCES, INC. (US) 2014-10-28 US disclosed
US-8871790-B2 Heterocyclic modulators of lipid synthesis 3-V BIOSCIENCES, INC. (US) 2014-10-28 US disclosed
EP-2683244-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V Biosciences, Inc. (US) 2014-01-15 EP disclosed
WO-2014008197-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2014-01-09 WO disclosed
WO-2014008197-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2014-01-09 WO disclosed
US-20120264737-A1 Heterocyclic Modulators of Lipid Synthesis 3-V BIOSCIENCES, INC. (US) 2012-10-18 US disclosed
US-20120264737-A1 Heterocyclic Modulators of Lipid Synthesis 3-V BIOSCIENCES, INC. (US) 2012-10-18 US disclosed
US-20120264737-A1 Heterocyclic Modulators of Lipid Synthesis 3-V BIOSCIENCES, INC. (US) 2012-10-18 US disclosed
WO-2012122391-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2012-09-13 WO disclosed
WO-2012122391-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. (US) 2012-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264737-A1 Heterocyclic Modulators of Lipid Synthesis FASN, FADS1, FADS2 CFTR 3857/4885PDK2 281/4885PDK4 261/4885
US-20230405016-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, FADS2 CFTR 4030/4885PDK2 243/4885PDK4 223/4885
US-20260048061-A1 COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS THRB, THRA, TSHR CFTR 2180/4885PDK2 2016/4885PDK4 853/4885
US-20240400552-A1 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FASN, FADS1, FADS2 CFTR 4048/4885PDK2 314/4885PDK4 271/4885
US-12551490-B2 Heterocyclic modulators of lipid synthesis FASN, FADS1, FADS2 CFTR 771/4885PDK2 1856/4885PDK4 1237/4885
US-20250017938-A1 COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS TSHR, FASN, THRA CFTR 2725/4885PDK2 1623/4885PDK4 702/4885
US-11622968-B2 Heterocyclic modulators of lipid synthesis FASN, FADS1, SCD CFTR 4000/4885PDK2 233/4885PDK4 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.